This paper discusses the mechanisms of S. aureus drug resistance including:(1)
introduction.(2) resistance to beta-lactam antibiotics, with particular emphasis on the mec …

Staphylococcus aureus is one of the leading hospital-associated and community-associated
pathogens, which has caused a global public health concern. The emergence of methicillin …

The lipopeptide daptomycin is used as an antibiotic to treat severe infections with gram-
positive pathogens, such as methicillin resistant Staphylococcus aureus (MRSA) and drug …

Emergence of drug resistance has created unmet medical need for the development of new
classes of antibiotics. Discovery of new antibacterial agents with new mode of action …

Daptomycin is a cyclic lipopeptide antibiotic, which was discovered in 1987 and entered the
market in 2003. To date, it serves as last resort antibiotic to treat complicated skin infections …

Rapid emergence of multidrug resistant Staphylococcus aureus infections has created a
critical health menace universally. Resistance to all the available chemotherapeutics has …

For many years, we have tried to use antibiotics to eliminate the persistence of pathogenic
bacteria. However, these infectious agents can recover from antibiotic challenges through …

Methicillin and vancomycin resistant Staphylococcus aureus infections are an emerging
global health concern leading to increasing morbidity and mortality. Continuous increase in …

Since the last century, methicillin-resistant Staphylococcus aureus (MRSA) bacteremia has
become a major global and public health concern not only in terms of morbidity and mortality …

Daptomycin is a last-resort membrane-targeting lipopeptide approved for the treatment of
drug-resistant staphylococcal infections, such as bacteremia and implant-related infections …